Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Allarity Therapeutics, Inc. ALLR

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 16, 2026 8-K 6 signals fired
Other
Patent Family Portfolio Disclosure Fast Track Designation Received Fast Track Granted Orphan Status Granted Expanded Access Program Active
Core
Indication Expansion
Sep 14, 2026 8-K 19 signals fired · top 15
Other
Protocol Amended Interim Data Positive Checkpoint Inhibitor Program Nyse Listing Disclosure Form S3 Shelf Registration Disclosure Enrollment Ahead Of Schedule Safety Differentiated Patient Retention High Expanded Access Program Active Publication Positive
Core
Clinical Trial Result Lead Asset Progress Indication Expansion Combination Therapy Mentioned
Biotech Risk
Clinical Hold Active
Aug 14, 2026 10-Q 16 signals fired · top 15
Other
Share Repurchase Activity Disclosed Net Loss Reported Cash Flow Statement Investing Activities Vie Primary Beneficiary Disclosure Covenant Compliance Affirmation Financing Activities Cash Flow Disclosure Liquidity Position Snapshot Disclosed Capital Raising Uncertainty Disclosed Other Income Expense Disclosure Market Volatility Risk Disclosure Equity Plan Board Approval Conditional On Shareholder Vote Shares Outstanding Disclosure Institutional Investment Ipo Or Capital Raising Completion Fair Value Hierarchy Disclosure
Aug 14, 2026 8-K 19 signals fired · top 15
Other
Protocol Amended Interim Data Positive Checkpoint Inhibitor Program Fast Track Designation Received Safety Differentiated Patient Retention High Enrollment Ahead Of Schedule Expanded Access Program Active Kol Endorsement Publication Positive
Core
Indication Expansion Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned
Biotech Risk
Clinical Hold Active
Jul 1, 2026 8-K 9 signals fired
Other
Interim Data Positive Patient Retention High Safety Differentiated Publication Positive Enrollment Ahead Of Schedule
Core
Indication Expansion Clinical Trial Result Combination Therapy Mentioned Lead Asset Progress
Jun 22, 2026 8-K 18 signals fired · top 15
Other
Protocol Amended Interim Data Positive Enrollment Ahead Of Schedule Checkpoint Inhibitor Program Fast Track Designation Received Safety Differentiated Patient Retention High Publication Positive Kol Endorsement
Core
Lead Asset Progress Clinical Trial Result Indication Expansion Combination Therapy Mentioned Clinical Hold
Biotech Risk
Clinical Hold Active
May 15, 2026 10-Q 19 signals fired · top 15
Other
Share Repurchase Activity Disclosed Net Loss Reported Cash Flow Statement Investing Activities Revenue Decline Explanation Financing Activities Cash Flow Disclosure Covenant Compliance Affirmation Liquidity Position Snapshot Disclosed Other Income Expense Disclosure Administrative Efficiency Fair Value Hierarchy Disclosure Ipo Or Capital Raising Completion Personnel Cost Decrease Disclosure Market Price Definition Debt Note Interest Terms Disclosed Equity Plan Share Reserve Disclosure
May 8, 2026 8-K 15 signals fired
Other
Protocol Amended Interim Data Positive Safety Differentiated Fast Track Granted Orphan Status Granted Fast Track Designation Received Patient Retention High Forward Looking Statement Definition Kol Endorsement Publication Positive
Core
Clinical Trial Result Combination Therapy Mentioned Indication Expansion Lead Asset Progress
Biotech Risk
Orphan Drug Designation
May 6, 2026 8-K 11 signals fired
Other
Enrollment Ahead Of Schedule Protocol Amended Interim Data Positive Expanded Access Program Active Kol Endorsement Patient Retention High
Core
Lead Asset Progress Patient Enrollment Velocity Indication Expansion Clinical Hold Regulatory Designation Only
Apr 28, 2026 8-K 2 signals fired
Core
Indication Expansion
Other
Patent Family Portfolio Disclosure
Apr 22, 2026 8-K 16 signals fired · top 15
Other
Protocol Amended Interim Data Positive Checkpoint Inhibitor Program Kol Endorsement Enrollment Ahead Of Schedule Safety Differentiated Fast Track Designation Received Publication Positive Expanded Access Program Active
Core
Clinical Trial Result Combination Therapy Mentioned Indication Expansion Lead Asset Progress Patient Enrollment Velocity
Biotech Risk
Clinical Hold Active
Apr 1, 2026 8-K 17 signals fired · top 15
Other
Net Loss Reported Protocol Amended Interim Data Positive Burn Rate Controlled Checkpoint Inhibitor Program Enrollment Ahead Of Schedule Administrative Efficiency Safety Differentiated
Core
Regulatory Designation Only Combination Therapy Mentioned Indication Expansion Lead Asset Progress Clinical Hold Patient Enrollment Velocity
Biotech Risk
Clinical Hold Active
Mar 30, 2026 10-K 57 signals fired · top 15
Other
Executive Educational Background Disclosure Audit Committee Independence Certification Board Committee Composition Disclosure Material Weakness In Internal Controls Disclosed Ipo Or Capital Raising Completion Net Loss Reported Classified Board Director Election Board Diversity Policy Disclosed Public Float Disclosure Tax Cuts And Jobs Act Disclosure Financing Activities Cash Flow Disclosure Fair Value Hierarchy Disclosure Protocol Amended Cash Flow Statement Investing Activities
Core
Clinical Trial Result